文献速递核素与放射性配体治疗肿瘤 PET/CT

[177Lu]Lu-FAP-2286治疗胸膜转移的初步结果与临床经验

Initial Results and Clinical Experiences of [177Lu]Lu-FAP-2286 for Pleural Metastases: A Single-Center Retrospective Study.
PubMed 文献 · J Nucl Med · 2026-04-01

这项单中心回顾性研究纳入17例经标准治疗失败的FAP阳性胸膜转移患者,接受中位2周期[177Lu]Lu-FAP-2286治疗。疾病控制率为59%,中位OS为17.3个月,中位PFS为4.1个月;达到疾病控制者OS显著更长(20.3个月 vs 6.4个月,P=0.004)。FAP PERCIST 1.0与RECIST 1.1评估一致率为86.7%,未报告3-4级不良事件。

要点

  • FAP阳性胸膜转移患者接受[177Lu]Lu-FAP-2286后疾病控制率达59%。
  • 达到疾病控制者中位OS为20.3个月,显著优于进展者的6.4个月(P=0.004)。
  • FAP PERCIST 1.0与RECIST 1.1评估一致率为86.7%,未见3-4级不良事件。

核心结论

  • [177Lu]Lu-FAP-2286在胸膜转移患者中显示出初步疗效和良好安全性,获得显著疾病控制和生存结局。
  • 该研究为FAP靶向放射性药物治疗该人群提供了真实世界证据,并提示FAP显像可用于疗效监测。

研究设计与样本

  • 单中心回顾性研究,纳入17例来自不同癌种、FAP阳性胸膜转移且既往接受过标准治疗的患者。
  • 患者接受中位2周期[177Lu]Lu-FAP-2286治疗,采用FAP PET/CT、CT和定性FAP SPECT/CT评估疗效。
  • 分析总生存期(OS)和无进展生存期,并报告不良事件(AEs)。

主要发现

  • 疾病控制率(非进展性疾病)为59%。
  • 中位OS为17.3个月,中位无进展生存期为4.1个月。
  • 达到疾病控制者中位OS为20.3个月,进展者为6.4个月(P=0.004)。
  • FAP PERCIST 1.0与RECIST 1.1评估的一致率为86.7%。
  • 治疗耐受良好,未报告3-4级不良事件,最常见为可管理的1-2级血液学毒性。

关键数值与推荐

  • 疗效评估采用FAP PERCIST 1.0和RECIST 1.1,两者一致率为86.7%。
  • 疾病控制定义为非进展性疾病,疾病控制率为59%。
  • 不良事件分级未报告3-4级,最常见为1-2级血液学毒性。

临床怎么用

  • 对于既往标准治疗失败的FAP阳性胸膜转移患者,[177Lu]Lu-FAP-2286可作为潜在治疗选择。
  • FAP显像可用于治疗反应监测,FAP PERCIST 1.0与RECIST 1.1评估一致性较高。
  • 治疗期间需关注血液学毒性,但本研究中均为1-2级且可管理。

局限性

  • 单中心回顾性研究,样本量较小(17例),结论需更大规模前瞻性研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cancer metastasis, particularly to the pleura, signifies advanced disease and poor prognosis. Fibroblast activation protein (FAP), which is highly expressed on cancer-associated fibroblasts, is a promising therapeutic target. This retrospective study investigates the efficacy and safety of the FAP-targeting radiopharmaceutical therapy [177Lu]Lu-FAP-2286 in patients with pleural metastases. Methods: Seventeen patients with FAP-positive pleural metastases from various carcinomas, all previously treated with standard therapies, received a median of 2 cycles of [177Lu]Lu-FAP-2286. Treatment response was assessed using FAP PET/CT, CT, and qualitative FAP SPECT/CT. Overall survival (OS) and progression-free survival were analyzed, and adverse events (AEs) were reported. Results: The disease control rate (nonprogressive disease) was 59%. Median OS was 17.3 mo, and median progression-free survival was 4.1 mo. Patients achieving disease control had a significantly longer OS (20.3 mo) compared with those with progressive disease (6.4 mo, P = 0.004). Response assessments using FAP PERCIST 1.0 and RECIST 1.1 showed a high concordance rate of 86.7%. Treatment was well-tolerated, with no grade 3-4 AEs reported. The most common AEs were manageable grade 1-2 hematologic toxicities. Conclusion: [177Lu]Lu-FAP-2286 therapy demonstrates promising preliminary efficacy and a favorable safety profile in patients with pleural metastases, achieving notable disease control and survival outcomes. This study provides real-world evidence supporting FAP-targeted radiopharmaceutical therapy as a treatment option for this patient population and suggests FAP-based imaging is useful for response monitoring. Larger, prospective studies are warranted to confirm these findings.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Li L, Ding H, Chen L, et al. Initial Results and Clinical Experiences of [177Lu]Lu-FAP-2286 for Pleural Metastases: A Single-Center Retrospective Study. J Nucl Med. 2026. PMID: 41571431. doi:10.2967/jnumed.125.271317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。